Design Controls Weren't Built for Models That Change
FDA is piloting exceptions rather than rewriting design controls for GenAI devices, leaving compliance leaders to build the continuous verification the rule doesn't require.
Insights
Field notes on working with AI, robotics, and security where compliance matters and the stakes are high.
The Real AI Device Risk Is Where FDA Doesn't Look Closely
Most AI-enabled devices clear FDA through the least rigorous pathway or avoid device classification entirely, leaving agentic AI's failure modes unexamined.
Functional Safety Meets AI Governance on the Plant Floor
ISO/IEC TS 22440 formalizes how AI intersects with functional safety just as EU AI Act high-risk rules and ungoverned agentic deployments collide on the factory floor.
The Other Compliance Clock for AI on the Plant Floor
As AI moves into industrial control systems, the EU Cyber Resilience Act and NIS2 impose a separate, faster-moving obligation than AI Act safety rules.
FDA's Lifecycle Bet on GenAI-Enabled Devices
FDA is easing premarket friction for AI-enabled devices while shifting the real compliance burden to post-market monitoring that current guidance cannot yet catch.
What FDA's Tempo Pilot Actually Asks Compliance Leaders to Decide
FDA's reported Tempo pilot lets generative AI devices reach patients ahead of authorization, and the public record on how is thinner than the headline suggests.
The Physical AI Business Case Has a Regulatory Hole
Industrial buyers are being pitched humanoid and physical AI capability faster than the safety classification and liability frameworks needed to deploy it responsibly.
Aviation's Assurance Gap Is Two Problems, Not One
Aviation safety leaders are being sold a single fix for what are actually two distinct AI assurance failures, and conflating them will leave both unaddressed.
The Vendor Concentration Risk Utilities Aren't Pricing In
As utilities wire agentic AI platforms into grid operations to capture real savings, few have updated vendor governance for critical infrastructure dependency.
Verification, Not Intelligence, Is Aerospace's Real AI Constraint
Aerospace is racing to apply AI to software and autonomy, but verification and explainability capacity, not model quality, is what will set the pace.
Architecture, Not Attestation, Is the New AI Vendor Test in Energy
As grid AI moves from pilot to production, energy operators must diligence vendor architecture and control enforcement, not just policy promises.
Design Controls Were Built for Outputs, Not Agentic Reasoning
FDA's total product life cycle framework for AI-enabled devices documents data lineage and output correctness, but not the intermediate process failures unique to agentic architectures.
Europe's Dual Certification Trap for Clinical AI
AI systems that influence clinical decisions can trigger MDR and EU AI Act obligations at once, and the Digital Omnibus timeline does not change that exposure.
FDA's GenAI Pilot Is Ahead of Its Own Guardrails
FDA's provisional pathway for generative AI devices exposes a verification gap that output benchmarks and existing life cycle rules were not built to close.
The Governance Debt Building in Drug Discovery AI
Regulatory frameworks are expanding toward AI in drug development, but the real exposure is a silent-failure risk that neither hype skeptics nor regulators are pricing in yet.
Grid AI's Lock-In Problem Is a Safety Case Problem
Utilities wiring AI into grid operations face a governance question that is less about data ownership than about who controls the safety case behind it.
In Physical AI Deals, Telemetry Rights Are the Real Asset
Energy and industrial AI transactions increasingly hinge on whether sensor and telemetry data remain usable after closing, not on the model itself.
Clinical Trials Are Running Agentic AI Faster Than Regulators Can Define It
Agentic AI now handles protocol deviation detection and trial monitoring, but no current framework tests for decision drift across autonomous runs.
The Quality Gate Aerospace Forgot to Govern
AI-driven First Article Inspection promises major efficiency gains, but aerospace manufacturers lack a governance layer to verify the verifiers.
Aviation's Assurance Gap Meets Autonomous AI
Aircraft certification and inspection regimes are built for deterministic systems, and the emerging autonomy stack is exposing what that model cannot see.
The Missing Layer Between Airworthiness and AI Assurance
Bilateral aviation certification still works for conventional hardware, but no framework yet governs the AI and autonomous systems entering the same operational footprint.
The Qualification Test That Redraws the AI Device Line
A new EU Court judgment on medical device qualification means AI tools built as informational or decision-support software may already sit inside MDR and IVDR scope.
The PCCP Gap: FDA Lets AI Models Change, Europe Asks Which Model You Meant
FDA's finalized change control plans let AI-enabled devices update without new submissions, but EU classification law may treat the same update as a new device.
The Next Safety Case Needs a New Kind of Evidence
Explainability and adversarial robustness are becoming safety-case requirements, and aerospace buyers should demand that evidence before regulators mandate it.
Agentic AI in Clinical Trials Isn't Exempt From High-Risk Classification
Agentic AI tools for trial design look administrative, but EU AI Act and MDR overlap rules can pull them into conformity assessment regardless of vendor intent.
When AI Agents Get a Direct Line to Physical Equipment
Standardized interfaces letting AI agents command industrial machinery force a functional safety decision that most operators have not yet made.
Decision Assurance Has No Tail Number
Aviation's directive model regulates known parts and configurations, but AI decision-making is already being governed elsewhere, with real gaps still unresolved.
The Non-Device Trap in EU Pharma AI
US pharma AI tools that avoid MDR device classification still face full exposure under the EU AI Act, GDPR, and EHDS.
The Blind Spot Beneath FDA's Generative AI Test
FDA's two-axis approach to generative AI devices is a familiar SaMD extension, but existing inspection data suggest most manufacturers can't yet clear the bar it sets.
The PCCP Illusion: Why US Speed Doesn't Buy EU Clearance
FDA's finalized change control pathway lets AI devices update without new submissions, but the EU AI Act demands continuous oversight that PCCPs were not built to satisfy.
The Deployer Question Utilities Haven't Asked
As AI takes over grid dispatch and demand response, energy and industrial firms need to determine their compliance status as AI deployers, not just adopters.
Who Certifies the Humanoid
Vendor consortiums are writing de facto safety standards for industrial humanoids faster than regulators can formalize them.
When AI Optimizes the Grid, Who Owns the Dispatch Call
AI now makes autonomous load-balancing and dispatch decisions across solar farms and virtual power plants, and no standard yet assigns liability for a bad call.
Off the Grid, Off the Record: AI's Energy Attribution Problem
As AI data centers bypass public grids with private power, buyers lose built-in metering and now need independent energy attribution to satisfy disclosure obligations.
The Readiness Gap Behind FDA's 1,000 AI Devices
FDA's large base of authorized AI-enabled devices masks a readiness gap that generative and agentic systems will expose immediately.
FDA's Three-Part Test for Agentic Devices
FDA's generative AI discussion paper outlines a safety, proficiency, and generalizability framework that will shape validation evidence long before formal guidance arrives.
Pharma's AI Pipeline Is Running on Two Regulatory Clocks
Drug discovery AI is accelerating faster than either the EU AI Act or FDA's generative AI framework can stabilize, forcing pharma to classify now or re-litigate later.
The Quality System Nobody Rebuilt Yet
FDA's living PCCP model for AI-enabled devices demands continuous evidence trails that most design control systems were never built to produce.
Two Safety Layers, One Machine: The Governance Gap in Physical AI
Vendor-native AI safety standards and established machine-safety codes are emerging in parallel, and industrial buyers must decide which one actually carries liability.
AI-Native Drug Discovery Needs Provenance Records, Not Just Speed
As generative AI moves into candidate generation and synthesis, sponsors must build data lineage and model audit trails before IND filing, not after.
Europe's AI Act and MDR Collide, and MedTech Wants a Rewrite
European MedTech is lobbying to revise how the EU AI Act and MDR/IVDR interact, and regulated buyers should build to the stricter combination now, not wait for the fix.
The Real Aerospace AI Bottleneck Is Evidence, Not Investment
Aerospace AI certification will be won by vendors who can automate verification evidence, not by whoever raises the most capital.
Two Speeds of FDA AI Clearance
The FDA's bounded-diagnostic clearances and its generative-AI comment period reveal a widening split in medical AI oversight that regulated buyers must plan around now.
The Materials Discovery Boom Aerospace Regulators Can't Yet Absorb
Generative AI is outpacing aerospace certification capacity, making evidence-ready validation the real constraint on new materials programs.
Europe's AI Act and MDR Are Being Rewritten at the Same Time
European regulators are revising the AI Act and MDR simultaneously, leaving life sciences compliance teams no stable baseline to build against.
FDA's Other AI Track: Drug Development Gets Its Own Playbook
While FDA's device guidance draws attention, a parallel track for AI in early-phase clinical trials and drug development is quietly taking shape.
FDA's Discussion Paper Moves the Goalposts on GenAI Devices
FDA's generative AI discussion paper signals a shift from one-time approval to continuous, competency-based testing that life sciences compliance teams should prepare for now.
FDA's New Deputy Commissioner Post Is the Real AI Signal
HHS is creating a dedicated technology leadership role at FDA, and that appointment will shape AI device oversight more than any single guidance document.
The Interlock Stays Dumb. Someone Now Has to Prove It.
A settled safety principle for industrial AI is starting to show up as a procurement requirement, not just a design rule.
Who Verifies AI Energy Attribution?
A new market for AI cluster energy attribution platforms is quietly becoming a compliance artifact, and regulated buyers need to ask who checks the numbers.
Verifying the Learned Robot, Not Just the Vendor's Claim
A vendor announcement about AI robot safety verification signals a real gap in industrial AI governance, but buyers should scrutinize the claim before treating it as a control.
The Trial Floor Is the Next Oversight Line, Not the Device Shelf
FDA's closed RFI on AI-enabled early-phase trials signals a second oversight track distinct from device review, and sponsors are moving faster than either.
FDA Is Assembling the Machinery Before It Finishes the Rule
FDA's device review architecture and new leadership roles point toward trial-side AI scrutiny, though the timeline and scope remain genuinely unsettled.
The Certification Machine Works. Autonomy Hasn't Earned a Seat Yet
Triple-certified business jets prove the FAA-EASA-ANAC pathway is mature, but aerospace has no equivalent framework for certifying AI as a flight-critical decision-maker.
The Safety Case Has a Blind Spot: The Grid Behind the HAZOP Assistant
AI-augmented HAZOP validation focuses on model accuracy, but the compute and energy infrastructure the model depends on is an unaddressed safety variable.
The Energy Layer Missing From Industrial AI Safety Cases
AI-augmented HAZOP is testing industrial AI safety cases, but the harder unresolved question is power and grid resilience, not just compute.
The Certification Evidence Trail Is Aerospace's Real Autonomy Constraint
Regulators keep reopening the evidentiary file on aircraft long after certification, a pattern that should worry anyone betting on fast autonomy approvals.
Clearance or Certification: Aerospace AI's Governance Fork
Aerospace AI adoption is splitting between use-case clearance frameworks and capability-specific certification, and buyers need to know which track applies before they scale.
When AI Agents Reach for the Controls
Anthropic's new agent-to-machine standard collapses the gap between AI recommendation and AI action, raising the stakes for industrial verification.
The Traceability Debt Building Inside AI-Native Drug Discovery
Closed-loop AI discovery platforms are compressing timelines faster than biopharma governance functions can build the audit trail regulators will eventually demand.
Cleared, Qualified, Authorized: Three Different Promises
Regulated buyers are treating FDA clearance, institutional platform qualification, and De Novo authorization as interchangeable seals when they carry different evidentiary weight.
The Recorder Gap: CVR Deadlines and the Separate Question of Machine Decisions
FAA CVR upgrade deadlines fix a human-decision recording problem, but certified automation and drone autonomy are advancing on entirely separate regulatory tracks with no equivalent record.
The Chip in the Loop: Delivery Drones and the Assurance Gap
Wing's evaluation of a new Nvidia AI module for delivery drones exposes an unresolved question: who owns the airworthiness case when compute hardware is sourced, not certified.
Robotaxi's Human-in-the-Loop Fight Is Coming for eVTOL
Guident's stance that robotaxi fleets still need human oversight previews the design choice that will decide how regulators certify autonomous flight.
The Platform Risk Hiding in Serial Clearances
Tempus AI's third ECG-based FDA clearance shows how one platform can accrete indications faster than buyers can verify its cumulative risk profile.
The Verification Problem Is Migrating From Policy to Protocol
As Anthropic formalizes how AI agents talk to machines, industrial verification is shifting from governance policy to interface protocol before regulators arrive.
Industrial AI's Real Bottleneck Is Who Signs Off On It
As industrial AI vendors race to automate control logic and physical machine operation, regulated operators still lack a named answer to who verifies the output.
When Plain English Writes the Control Logic
AI-native industrial controllers promise to replace retiring PLC engineers, but the safety case now depends on verifying generated logic, not just trusting it.
Device Clearance Outpaces Practice Governance
Tempus's third FDA-cleared AI-ECG tool shows the 510(k) pathway working smoothly, while new pharmacy guidance reveals governance gaps at the point of use.
The CVR Upgrade Deadline Is an AI Data Decision in Disguise
FAA's cockpit voice recorder mandate is a hardware deadline today, but the data architecture choices made now will determine how AI safety analytics work later.
Life Sciences Is Merging Two EU AI Act Obligations Into One
EU AI Act transparency rules for content marking and interaction disclosure are distinct obligations, and life sciences compliance teams keep treating them as one.
FDA's GenAI Guidance Gap Puts Lifecycle Design on the Critical Path
FDA is still soliciting input on generative AI device oversight while conventional AI/ML tools keep clearing through 510(k), forcing sponsors to design lifecycle monitoring ahead of guidance.
The Trust Gap in Industrial AI
Industrial AI's $70 billion opportunity by 2030 depends less on model accuracy than on whether engineers can verify recommendations before acting.
Quantum-Classical AI Enters Drug Discovery, Validation Frameworks Don't
Quantum-enhanced generative AI is moving into drug discovery pipelines faster than GxP validation and data integrity practices can absorb it.
Vertical AI's Pitch Meets a Regulatory Reality Check
A sponsored case for vertical AI in utilities collides with a real state-level regulatory split, and the fix is narrower than a single governance framework.
The Sensor and the Exploit Now Share the Same Rail
A federal warning on AI-generated PLC exploits shows industrial AI's safety gains and its security exposure now sit on the same infrastructure.
The Next Regulatory Question Isn't the Model. It's the Data It Rescued.
AI-driven reanalysis of failed clinical trials is producing new evidence outside the systems built to validate it, and GxP quality frameworks have not caught up.
The Liability of Knowing First
Predictive safety AI on construction and industrial sites creates a documented knowledge trail that shifts liability the moment an alert goes unanswered.
Approved Supplier Status Is Not a Certification
A Gulfstream cockpit display supplier's new approved status highlights a gap buyers routinely miss between OEM qualification and airworthiness certification.
Dual-Use Ambition and the Certification Fork
Whisper Aero's move toward both civil and defense markets shows why buyers must ask which certification regime an AI-enabled aircraft's assurance evidence actually targets.
EMA Moved First on AI. FDA Is Still Deciding How.
EMA's lifecycle-wide AI reflection paper and FDA's still-open genAI device rulemaking are running on different clocks, and neither is finished business for regulated buyers.
The EU AI Act Extension Is a Delay, Not a Reprieve
The Digital Omnibus pushes the EU AI Act high-risk deadline for medical devices to August 2027, but MDR/IVDR and EMA already require the same work now.
FDA's GenAI Framework Is Still a Draft of a Draft. That's the Opportunity.
FDA's two-axis risk framework for generative AI medical devices is not policy yet, and the October 19 comment window is the cheapest chance to shape it before it hardens.
The Icing Gap: What EASA's Admission Means for AI-Based Hazard Detection
EASA's warning that atmospheric icing remains poorly understood exposes a governance blind spot for AI systems built to detect and predict physical hazards.
AI Threat Detection Is Moving to Orbit Faster Than Assurance Can Follow
Space operators are adopting AI-enabled threat detection and zero-trust architectures with no sector-specific certification regime to verify the claims.
The Verification Bottleneck in Physical AI
As robot installations and physical AI deployments hit record volume, safety verification infrastructure, not the AI itself, is becoming the binding constraint on scale.
The Grid Is Getting a New Operator, and It Isn't Human
AI systems are shifting from consuming grid power to making real-time dispatch decisions, and that reclassification changes who is accountable when something goes wrong.
The Skills Gap AI Is Widening, Not Closing
Industrial operators are deploying AI hazard detection to cover a labor shortage, but the human judgment needed for the unmodeled event is eroding faster than the AI's competence grows.
The Optimization Loop Is Outrunning the Safety Case
AI now adjusts biogas and energy storage processes continuously, but the permits and safety cases governing those processes were built for static setpoints, not real-time control.
Autonomous Airspace Coordination Is Outrunning Its Certification Path
NASA's Phase II award for an AI-driven airspace coordination network exposes a widening gap between deployable autonomy and the certification frameworks meant to govern it.
Clinical AI's Financial Case Is Made. Its Audit Trail Isn't.
Drug discovery and trial AI are proving their financial return faster than sponsors are building the validation records to defend that work at inspection.
The Contrail Trial Is Also an AI Act Compliance Test
Google and NATS are piloting AI contrail-avoidance forecasts inside live UK airspace, putting EU AI Act high-risk obligations to their first real operational test.
The EU AI Act Extension Is Not the Relief It Looks Like
Brussels pushed back the high-risk AI Act deadline for regulated medical devices, but MDR and IVDR certification bottlenecks did not move with it.
EASA's Icing Warning Is an AI Validation Problem, Not Just a Weather One
EASA's admission that atmospheric icing remains insufficiently understood exposes a hidden validation gap for AI-enabled ice detection and anti-icing systems.
Physical AI Needs an Override Standard, Not a Trust Layer Brand
As AI systems actuate breakers and throttle industrial assets, buyers need a certifiable override standard, not a vendor's proprietary trust claim.
When AI Tunes the Process, Which Framework Governs the Record?
AI process control is now shaping regulated credit claims in biogas and RNG production, and no framework yet specifies who audits the machine's decision trail.
The Safety Gains Are Real. So Is the Skill You're Losing.
AI-driven hazard detection is cutting industrial incident rates while quietly eroding the human judgment regulators and insurers still assume workers have.
The Doctor Test for AI Devices
FDA's move toward clinician-style, ongoing assessment of AI-enabled devices reshapes what counts as durable evidence, ahead of any final guidance.
The Governance Gap Belongs to the Deployer, Not the Regulator
Hospitals and pharma functions adopting generative AI now carry governance obligations that device and drug frameworks were never built to cover.
Insuring the Unflown: Aviation AI Has No Loss History
As AI moves into cockpits, MRO, and eVTOL, insurers are underwriting aviation risk with no actuarial base, forcing buyers to substitute governance evidence for loss data.
The AI Lifecycle Decision Medtech Can't Wait to Make
J&J's Monarch clearance shows predetermined change control plans already govern AI updates, a lifecycle discipline device makers need now, not after genAI guidance lands.
Who Signs the Maintenance Log When AI Wrote the Recommendation
As engine MRO providers adopt AI decision support, liability for AI-informed maintenance calls remains unallocated between vendor, MRO, and insurer.
Physical AI's Safety Layer Can't Be One Vendor's Story
Regulated buyers deploying physical AI should demand safety verification independent of the vendor, matching the standard ISO 42001, the EU AI Act, and FDA/MDR pathways already set.
Record Robot Installations Prove Demand, Not Readiness
Global industrial robot deployment is hitting record highs, but the compliance question buyers face is verification under live conditions, not unit counts.
The Compliance Question Surrogate Models Can't Answer
AI surrogate models are replacing validated engineering and lab tools faster than ISO 42001, the EU AI Act, and FDA regimes can absorb them.
The Labor Shortage Machines Were Built to Fix Is Creating a Skills Debt They Can't Repay
Record industrial robot deployment is solving a headcount problem while quietly eroding the human competency base that AI oversight regimes assume still exists.
The Contrail Trial Exposes a New Kind of Aviation AI Risk
A North Atlantic contrail avoidance trial shows how AI-driven environmental claims and rerouting decisions are outrunning verification and liability frameworks.
The FDA Is Still Asking Questions. Brussels Already Moved Its Clock Once.
FDA's open genAI comment period and the EU's already-shifted AI Act deadlines argue for building the shared lifecycle core, not betting on either jurisdiction's paperwork.
The Industrial AI Safety Gap Is a Dataset Problem You Can Now Measure
A new industrial inspection benchmark and a wave of safety-layer capital give buyers a way to test vendor hazard-detection claims instead of trusting them.
The Real AI Governance Gap Sits Behind the Flight Deck
AI is spreading into MRO records, ground operations, and flight planning faster than certification frameworks can follow, and the risk is accumulating off-camera.
Generative AI Isn't Breaking Device Rules. It's Avoiding Them.
FDA's generative AI vacuum in clinical SaMD is pushing vendor activity toward drug discovery applications that sit outside device regulation entirely.
Physical AI Safety Is Being Priced Ahead of the Standard That Should Define It
Capital markets are pricing autonomous-machine safety infrastructure before regulators have defined what a defensible hazard dataset looks like.
When AI Stops Advising and Starts Operating the Grid
As AI shifts from analytics to closed-loop control in energy and industrial systems, validation and human-override design become the real governance test.
AI Drug Discovery's Capital Boom Sits Outside the Regulatory Perimeter, Not Ahead of It
Discovery-stage AI funding is surging, but the mismatch compliance leaders should track is structural, not a simple case of regulation lagging money.
When Energy Optimization Software Becomes Grid Infrastructure
AI systems making real-time energy allocation decisions across generation, storage, and grid draw are being bought as software, not governed as infrastructure.
AI Is Entering the Maintenance Record, Not Just the Cockpit
As MRO providers adopt AI for engine maintenance decisions, the real test is whether audit trails can withstand FAA and EASA scrutiny.
Aviation Is Deploying AI Faster Than It Can Certify It
MRO, cockpit, and airspace AI are advancing across aviation while the FAA still lacks a settled safety assurance method, raising airworthiness and liability exposure.
Aviation's AI Decisions Are Outrunning Its Liability Maps
Insurers are repricing aviation AI risk before liability attribution is settled, and the counterargument that human oversight still anchors accountability deserves scrutiny too.
Aviation's Climate AI Needs a Verification Standard, Not Just a Model
As airlines and regulators lean on machine learning to forecast and verify contrail avoidance, the missing piece is an audit standard for the claims themselves.
FDA's Postmarket AI Machinery Is Still Under Construction
Recent FDA moves on AI-enabled devices signal a postmarket framework taking shape, but the agency's own uncertainty argues against treating early engagement as a settled strategy.
The FDA-EU Fork in AI-Enabled Medical Devices
FDA is building adaptive, lifecycle-based pathways for AI-enabled devices while the EU stacks AI Act obligations atop MDR and IVDR, forcing a sequencing decision now.
The Generative AI Gap in FDA's Device Playbook
FDA has cleared over 1,000 AI-enabled devices, but generative AI features still lack a defined regulatory pathway, forcing sponsors to choose their architecture carefully.
The Two Blind Spots in AI-Powered Safety Inspection
Industrial AI vision systems for hazard detection are only as strong as their training data and the human skills they quietly displace.
When AI Simulation Becomes Certification Evidence
Aerospace and industrial manufacturers are swapping physics simulation for AI surrogate models, and certification frameworks have not caught up.
Aviation Has a Proving Ground. It Just Doesn't Know It Yet.
A contrail trial, a maintenance rollout, and a pilot-training study show aviation already runs AI proving grounds ad hoc, with no structure connecting them.
The Evidence Gap PV Automation Never Has to Close
FDA's mounting scrutiny of AI medical devices reveals evidence gaps even for cleared products, while pharmacovigilance AI faces no such test at all.
The Extended Clock Is Not a Reprieve
The EU AI Act's delayed enforcement dates for medical device AI give sponsors more runway, but only if they use it to align MDR/IVDR and AI Act evidence now.
The Comment Window That Will Define GenAI Medical Devices
FDA's open docket on generative AI medical devices is the narrow window life sciences leaders have to shape binding rules before they harden.
The 72/10 Problem: Why Industrial AI Stalls Before It Scales
Most manufacturers have deployed AI, but only a tenth scale it, and the gap is governance, not algorithms.
ISO 42001 Gets a Precedent, Not a Verdict
NADEC's ISO 42001 certification gives industrial AI buyers a reference point, but one certificate does not settle whether the standard closes the gap between documented control and operational reality.
The Architecture Decision Pharmacovigilance AI Cannot Defer
Cross-jurisdictional data rules are forcing pharma safety teams to choose between centralized and localized AI architectures before regulators force the choice for them.
The Quiet Successor: AI as Institutional Memory in Industrial Plants
As agentic AI fills the knowledge gap left by a shrinking industrial workforce, firms need an audit trail for what the AI is teaching, not just what it automates.
The Grid's New Feedback Loop: AI Managing the Load AI Creates
AI-driven data center demand is pushing utilities toward AI-managed storage and dispatch, quietly expanding critical infrastructure governance exposure.
Type Certified in Europe. Exempted in America.
The Velis Electro's patchwork of approvals shows that electric aircraft certification does not travel across borders the way buyers assume.
Pilots Are Flying With AI Already. Nobody Has Agreed How to Check It.
FAA and EASA acknowledge aviation lacks a settled method to assure AI safety in cockpit systems, leaving airlines and OEMs to build evidence without a fixed target.
FDA Clearance Is Not the Evidence Trail
FDA-authorized AI devices are outpacing the evidence behind their safety and equity claims, leaving health systems to build the diligence layer themselves.
The FDA's Open Docket Is the Real Deadline
FDA's move toward assessing generative AI devices like clinicians raises real feasibility questions, but sponsors who wait for guidance will lose the argument.
The Underwriters Are Becoming the Real AI Certifiers
As aviation AI outpaces formal safety assurance, insurers are quietly setting the terms buyers must satisfy to fly.
The PCCP Is the Real Decision, Not the Generative AI Docket
FDA's Predetermined Change Control Plan guidance, not the open generative AI docket, is the mechanism sponsors must decide on now for AI-enabled devices.
When the Robot Doesn't Fit the Category
AI-enabled humanoid and mobile robots are blurring the line between industrial and collaborative machines, forcing a safety classification decision before deployment.
When the Simulation Becomes the Surrogate: Aerospace Certification Meets Statistical Models
Aerospace engineering teams are swapping physics-based simulation for AI surrogates in compliance workflows, and airworthiness certification has no settled answer for auditing that substitution.
When AI Stops Advising and Starts Actuating
Agentic AI is moving from dashboards into direct control of industrial and grid operations, and assurance frameworks have not caught up.
Clearance Was Never the Finish Line
FDA's predetermined change control pathway shifts the real compliance burden from initial authorization to lifecycle governance of AI models after they ship.
Industrial AI's Talent Pitch Assumes a Workforce It Is Depleting
The industrial AI augmentation narrative depends on a senior verification workforce that the same labor shortage driving AI adoption is actively removing.
Airworthiness Is Becoming a Property of the System, Not the Aircraft
FAA's Part 108 drone framework and live AI forecasting in ATC decisions show certification shifting from airframes to software stacks that update faster than any type cert.
Aviation Is Building a Second Certification Track for Autonomy
EASA's SAIL rating for Shield AI's V-BAT signals that autonomy and inference stacks now need their own assurance case, separate from the airframe.
The Real Gap Isn't Evidence. It's Framework Fit.
AI medical device clearances are outpacing the regulatory architecture meant to govern them, and hospitals are deploying generative AI ahead of any classification at all.
The Governance Gap FDA's Rulemaking Won't Reach
FDA is still asking questions about generative AI in medicine while health systems already run it inside clinical workflows unmonitored.
When AI Starts Moving the Machinery
Agentic AI is shifting from advisory dashboards to direct control of refinery and plant equipment, and the safety case ownership question has not caught up.
When the Coder Is an Unrated Component
AI coding agents now modify production software with no aviation-grade assurance framework, a gap regulated buyers cannot ignore.
Cleared Is Not Validated: The Evidence Gap Behind FDA's AI Device Count
FDA's public summaries for AI-enabled devices were built to demonstrate fairness, but their format makes that fairness nearly impossible to verify.
Aviation's AI Template Has a Recognition Problem
Aviation's tiered certification model is becoming AI governance's default architecture, but its unresolved cross-border recognition gap should worry regulated AI buyers just as much.
Aviation-Grade AI Governance Is Borrowing Credibility From an Unsolved Problem
Tech firms want AI incident forensics modeled on aviation, but aviation regulators admit they lack a settled method for AI safety assurance.
Validation Travels. Workarounds Don't Scale.
Aviation shows a real difference between mutual-recognition validation and bilateral workarounds, and AI governance buyers need to know which one they're building.
The Safety Wearable Is Now a Regulated Decision-Maker
Biometric and proximity safety wearables in energy and industrial plants are starting to meet the legal definition of automated decision-making technology.
The PCCP Is the Real Clearance
FDA's predetermined change control plans, not the original device clearance, now define how far an AI-enabled medical device can drift without new review.
The Governance Gap in Clinical Trial Operations AI
Agentic AI is spreading through trial enrollment, monitoring, and feasibility work faster than FDA, EU AI Act, or ISO 42001 pathways built for medical devices can reach it.
The Black Box Analogy Only Works With an NTSB Behind It
Nvidia's push for AI agent flight recorders borrows aviation's most visible artifact while skipping the investigation infrastructure that makes it useful.
AI Clinical Decision Support Is Scaling Past Its Evidence
FDA clearance and predetermined change control plans govern AI software lifecycle, not clinical benefit, leaving hospitals to own the evidence gap.
The AI Drug Discovery Boom Is Outrunning Trial Execution
Generative AI is accelerating molecule design, but no AI-discovered drug has cleared trials, and regulators have yet to define how AI governs the trials themselves.
When AI Enters the Safety Loop, Deterministic Standards Start to Bend
Refiners and manufacturers are putting AI inside safety-critical decisions, but the verification standards built for deterministic control were never designed for it.
The Clinical Trial Has No AI Rulebook
Sponsors are deploying AI across trial execution with no dedicated regulatory framework, leaving GCP and data integrity obligations to fill the gap alone.
The EU AI Act Grace Period Is a Countdown, Not a Pause
Brussels pushed high-risk AI enforcement for medical devices to 2027 and 2028, but the multi-year MDR/IVDR build-out clock is already running.
Clinical Decision Support AI: Cleared, Not Proven
High-risk AI clinical decision support is scaling through FDA and IVDR pathways faster than its evidence base, leaving compliance leaders to close the gap regulators haven't.
The Plane Crash Analogy Only Works If the Toolchain Backs It Up
Tech giants want AI failures treated like aviation incidents, but that framing only holds if the underlying toolchain carries real qualification evidence.
Autonomous Landings Need Their Own Black Box
Airbus's AI landing trial and Nvidia's push for AI action logs point to the same gap: aviation certification demands auditable evidence, not just working code.
The AI Safety Layer Is Outrunning Its Own Certification
Refiners and manufacturers are embedding AI into safety-critical decisions faster than functional safety and cobot standards can validate them.
For the C919, Certification Is the Product
COMAC's C919 shows that airworthiness certification, not airframe performance, is what actually gates access to global aerospace markets.
The EU AI Act Reprieve Is a Timing Bet, Not a Pause
Digital Omnibus alignment gives AI-enabled medical devices breathing room on paper, but MDR/IVDR certification obligations have not moved and neither has the underlying risk.
Grid AI Capital Is Moving Faster Than the Proof Behind It
Energy infrastructure capital is being allocated to AI-driven grid modernization faster than utilities can document what that AI actually delivers.
Airworthiness Doesn't End at Certification. For AI, It Can't.
A new AFWERX contract for real-time model health monitoring signals that AI assurance in defense and aerospace must be continuous, not a one-time certification event.
The Safety Sensor Just Turned Toward the Worker
Driver-monitoring AI is migrating from vehicles to factory floors, turning workers into the sensor layer and pulling connected-worker tech into EU AI Act high-risk territory.
Two Curves, One Decision: Agentic AI's Control Authority Is Outrunning Its Oversight
Industrial operators are handing agentic AI direct control authority faster than monitoring tools can verify it, and buyers need a risk tier to tell the two apart.
Airbus's AI Landing Trial Is Modest. The Certification Question It Raises Isn't.
Airbus's Mistral-assisted landing trial is workload automation, not autonomy, but it still exposes gaps in how aviation certifies learned software.
AI Can Design a Drug. It Still Can't Get One Approved.
Generative AI is accelerating drug candidate design, but no AI-discovered molecule has reached approval because clinical trial execution and its regulatory footing remain unresolved.
The C919's Real Test Isn't Mongolia. It's the Bilateral Chain Behind It.
COMAC's first international C919 flight bypasses FAA and EASA certification entirely, and the bilateral recognition strategy behind it deserves more scrutiny than the headline route.
Explainable AI for Defense Systems Is Still R&D, Not a Certified Capability
Fresh SBIR funding for real-time model health monitoring shows explainable AI assurance in defense aerospace remains pre-competitive research, not a purchasable safeguard.
The Evidence Gap Behind AI Clinical Decision Support
AI decision support tools are scaling into hospitals faster than the evidence and oversight infrastructure needed to trust them.
The Vendor Blind Spot Now Living Inside Your Equipment
Frontier labs took weeks to notice their own models were hijacked, and that detection lag is now embedded wherever industrial vendors build on those models.
The Clearance Isn't the Risk. The Change Control Plan Is.
As high-risk AI medical devices scale, the decisive diligence question shifts from FDA clearance status to what a manufacturer's change control plan permits it to alter unsupervised.
Chip Equipment Orders Are Writing AI Governance Nobody Has Defined Yet
Samsung and SK hynix are mandating embedded AI agents in new equipment orders faster than ISO 42001 or the EU AI Act can define what compliant industrial AI actually requires.
Static Certification, Shifting Models: What's Actually New
The gap between one-time AI certification and continuous model drift is old news; the funding and liability questions forming around it are not.
What You Didn't Automate Is Now a Governance Artifact
As industrial AI deployment accelerates unevenly, the decision to withhold automation is becoming as auditable as the decision to deploy it.
The Money Is Ahead of the Rulebook in Trial AI
Capital is flooding into AI for clinical trial conduct while regulators have yet to define what governs it, leaving sponsors exposed.
When the Algorithm Is the Biomarker
Computational pathology AI blurs device and biomarker regulation, but predetermined change control plans, not model freezing, may be the real fix.
A Recorder Is Not an Investigator
AI vendors are borrowing aviation's black box for accountability, but the metaphor skips the investigative infrastructure that actually makes it work.
The Exemption Your CDS Tool Is Standing On Is Under Review
FDA's Section 3060 review of clinical decision support flexibilities means hospitals should stop assuming their AI-driven CDS tools sit outside device regulation.
The Compliance Clock Slowed. The Physical Risk Didn't.
EU AI Act delays and carve-outs for industrial AI are widening the gap between regulatory relief and unresolved physical-world safety science.
MedTech Diligence Now Has to Read Change Plans, Not Just Technical Files
AI-enabled devices are adding predetermined change control plans to MDR/IVDR technical files, and buyers evaluating MedTech targets need to diligence both.
The PCCP Window Before the AI Act Deadline Closes
IMDRF's new PCCP principles and the EU AI Act's delayed medtech deadline create a narrow window to build one change control architecture instead of two.
Power Ahead of the Grid, Ahead of the Rules
Gigawatt-scale AI data center power deals are outrunning both utility interconnection and AI safety regulation, leaving operators to self-govern autonomous grid control.
Who Revalidates the Model
As industrial AI moves into design control, inspection, and compliance monitoring, lifecycle re-validation, not deployment speed, becomes the real audit risk.
The EU AI Act Delay Buys Time, Not Cover
Extended EU AI Act deadlines and product-safety carve-outs shift industrial AI risk onto existing machinery and quality regimes, not away from scrutiny.
The Change-Control Gap Between MDR and the AI Act
Predetermined change control plans reveal the specific reconciliation gap between MDR/IVDR certification and EU AI Act obligations for adaptive medical algorithms.
The MedTech Compliance Asset Has a Shelf Life
MedTech buyers are pricing compliance documentation as a deal asset, but the standards that file is graded against are still being written.
The PCCP's Global Convergence Is a Hypothesis, Not Yet a Standard
IMDRF has laid out principles for regulators to adopt predetermined change control plans, but FDA and the EU's MDR/IVDR regime remain far from aligned.
FDA's RWE Guidance Widens the Door. It Doesn't Lower the Bar.
FDA's final real-world evidence guidance broadens what device sponsors can submit, but the decision that matters is whether data pipelines can meet the traceability bar the broader door implies.
AI Drug Discovery's Evidence Gap
Billions have flowed into AI drug discovery with zero FDA approvals, and the bottleneck is evidence infrastructure, not molecule generation.
Ambient Voice AI Just Crossed the Medical Device Line
MHRA guidance on ambient voice technology signals that clinical AI scribes and voice assistants are now squarely inside medical device regulation, not adjacent to it.
The EU AI Act's Lighter Touch Is Not a Lighter Burden
Extended deadlines and narrower scope for industrial AI under the EU AI Act shift compliance obligations onto existing safety and quality frameworks rather than removing them.
In HealthTech M&A, AI Governance Is Now a Line Item on the Term Sheet
Buyers in HealthTech and MedTech deals are pricing AI governance maturity directly into valuation, not treating it as a closing condition.
One Journal Article Is Not Yet an AI Audit Standard
A single peer-reviewed framework is being framed as the working audit standard for generative AI mental health tools, and compliance leads should treat that framing with more caution than the coverage suggests.
Defense AI Certification Is Becoming a Two-Track Problem
Runtime monitoring is emerging alongside, not instead of, pre-deployment certification, and buyers need to hold vendors accountable for both.
Lab-Safe Is Not Field-Safe: The Physical AI Validation Gap
Industrial robotics and machine vision are outpacing safety validation methods built for static, deterministic systems, forcing a shift to continuous lifecycle monitoring.
The Calibration Analogy Doesn't Hold, and That's the Real Problem
Quality teams are borrowing instrument-calibration logic for AI drift, but the metrology underneath doesn't transfer, and that gap is where audits will fail.
AI Discovers Drugs. It Doesn't Approve Them.
AI drug discovery has drawn billions in investment but zero FDA approvals, and the bottleneck sponsors need to plan for is evidence, not speed.
MDUFA VI Is a Capacity Signal, Not the Whole Story
The MDUFA VI negotiation matters for AI device review capacity, but sponsors treating it as the sole variable are missing parallel forces already shaping their timelines.
A Journal Article Is Not a Regulatory Safe Harbor
A Nature Medicine audit framework for AI mental health tools is being framed as a de facto FDA standard, but no published mechanism makes that so.
Surgical AI's Classification Is a Bet, Not a Badge
Medtronic's Aide platform is cleared as a low-risk data system, but AI-assisted surgery is moving toward active guidance faster than that classification can hold.
Aerospace Has Two Kinds of AI Assurance. Agentic Systems Need a Third.
Certification and model health monitoring both fall short of testing whether an agent's decision loop can be manipulated before it acts.
Autonomous Landings Won't Clear Certification on Capability Alone
Airbus's AI landing trials and new explainability mandates show FAA and EASA will certify model behavior, not just performance.
The Closed-Loop Question: When Industrial AI Agents Get to Act Alone
Zero-miss safety trials and closed-loop agents are pushing plant leaders to decide how much autonomy AI gets inside existing quality and safety systems.
When the Regulator's Capacity Becomes Your Risk
FDA's shrinking resourcing and the MDUFA VI negotiations mean AI device sponsors can no longer treat PCCP approval as the end of verification.
Three Regulators, Three Clocks, One AI-Enabled Device
The EU, US, and China are each running statute ahead of certification infrastructure for AI-enabled medical devices, and manufacturers need one documentation architecture, not three.
Who Owns the Compliance Layer When Vendors Acquire It
Dassault's purchase of ArisGlobal and Red Hat's open agent-safety project show two competing paths for AI governance, and industrial buyers must pick one before they scale agentic AI.
Aerospace's AI Bottleneck Is Not the Model. It's the Validator.
As AI accelerates inspection, simulation, and structural analysis, the scarce resource is the credentialed workforce who can defend that evidence to FAA and EASA.
The Assurance Gap Agentic AI Exposes Isn't Aviation's Alone
Agentic AI breaks the deterministic testing model behind DO-178C, and the same structural gap is emerging across ISO 42001, EU AI Act, and FDA regimes.
Three Regulators, Three Different Bets on AI Medtech
The EU, the US, and China are sequencing AI device oversight in opposite orders, and compliance leaders need to plan for all three.
AI Defect Detection Is Outrunning the Production Certificate
Deep learning inspection is moving onto aerospace production lines faster than FAA production certificate holders can document its evidentiary basis.
The Oversight Question Autonomous Diagnostic AI Hasn't Answered
FDA's latest device clearances shift AI from assistive to autonomous interpretation, and compliance teams still lack a shared standard for human oversight.
HealthTech Buyers Are Pricing Compliance Before the Rules Agree With Each Other
Diligence teams valuing AI-enabled health devices are treating EU AI Act readiness as a settled asset, but FDA, EU, and China are still diverging on what that documentation must show.
The Inspection Layer's Governance Gap
Deep learning inspection tools are moving into FDA and MDR/IVDR-regulated production lines faster than the validation methods built to certify them.
When Energy AI Stops Monitoring and Starts Dispatching
AI systems are moving from monitoring power infrastructure to executing real-time control decisions, and operators lack a governance layer for who authorized that authority.
The Speed-to-Power Trade Nobody Is Underwriting
AI data center demand is spawning a market of grid speed-to-power intermediaries, and industrial buyers need a governance answer before they sign.
Two Risk Ledgers, One Autonomous Agent
Industrial AI autonomy and AI agent security are the same governance question asked from opposite ends, and only one side has drawn real investment.
Life Sciences AI Is Moving at Two Different Speeds
Diagnostic AI is clearing FDA review on schedule while AI-native drug discovery still has zero approvals, and the gap is documentation, not science.
When Safety AI Stops Advising and Starts Acting
Industrial AI agents are moving from flagging safety risks to raising incidents autonomously, forcing operators to define authority limits before regulators do.
The Documentation Debt AI Drug Discovery Keeps Repeating
AI drug discovery's funding-to-approval gap echoes a governance failure regulators have already documented in medical devices, and the fix is the same.
Plant-Floor AI Agents Are Closing the Loop Faster Than Governance Can Follow
Industrial AI agents are moving from advisory copilots to closed-loop actuation, and the audit infrastructure to govern them is still catching up.
Direct Delivery Authorization Is Colliding With AI-Driven Inspection
SAE's updated supply chain standard loosens incoming inspection just as AI-based NDT and optical inspection take over quality gates, raising a validation gap buyers must close.
The Governance Gap Behind FDA's AI Device Surge
FDA's AI-enabled device authorizations are scaling faster than lifecycle governance infrastructure, and the same gap is now stalling AI drug discovery approvals.
The Governance Tooling Decision Behind Agentic AI Rollouts
A new open source coalition for AI governance testing forces energy and industrial buyers to choose between proprietary control stacks and shared standards.
Aerospace's AI Bottleneck Is the Signature, Not the Software
AI can generate stress analysis and defect findings faster than engineers can validate them against FAA and EASA standards, and that verification capacity is the real constraint.
Agentic AI Is Outrunning Aviation's Security Testing Playbook
Drone swarms and other agentic systems are entering aviation and defense procurement faster than security testing methods built for passive software can assess them.
The Convergence Gap in AI Life Sciences Regulation
Regulators describe AI, digital health, and clinical trial law as converging, but FDA, UK, and Chinese actions show the frameworks are still moving on separate, misaligned tracks.
Agentic AI Is Outrunning Machine Safety Certification
Autonomous industrial and life sciences AI is now acting inside control loops that IEC 61508, EU AI Act risk tiers, and MDR/IVDR were not built to certify.
AI Governance's Real Fault Line Is Classification, Not Geography
Divergence in AI rules across the US, EU, and China is driven less by geography than by conflicting definitions of what counts as a regulated AI function.
Health AI Is Straining Categories, Not Just Rules
US data provenance, UK product classification, and Chinese jurisdictional scope are all cracking under AI health tools that don't fit pre-AI regulatory taxonomy.
Two New Fast Lanes for AI Devices, No New Evidence Standard
EU and FDA are both building faster pathways for AI medical devices, but neither has defined what evidence should earn a device the fast lane.
In Autonomous Flight AI, the Certification Pathway Is the Product
Regulated buyers evaluating aerospace autonomy startups should underwrite the type certificate partnership, not the model's performance claims.
The Clinical AI Governance Gap Is Structural, Not Accidental
The regulatory perimeter around clinical AI is contested by design, and the same gap is opening upstream in drug development.
Routine Health Data Is Fueling AI Devices Faster Than FDA Can Define the Standard
FDA's December 2025 real-world evidence guidance lets sponsors train AI devices on routine health data, but provenance and bias standards remain undefined.
ISO 9001's AI Update Is a Signal, Not a Substitute
ISO 9001's revision pulls AI-influenced decisions into quality documentation, but it does not replace ISO 42001, the EU AI Act, or sector-specific AI governance.
Compliance Is Becoming a Data Problem, Not a Paper One
India's mandate for machine-readable product standards previews a structural shift industrial AI buyers cannot ignore: verification against static documents will not scale.
Simulation-Guided Trials Are Ahead of the Law
Digital twins and virtual control arms are entering pivotal trial design faster than GDPR and MDR frameworks can validate the data behind them.
When AI Guides the Hands, Not Just the Read
FDA's clearance of real-time ultrasound guidance AI creates a task-shifting risk category that standard imaging AI governance does not address.
AI Is Writing Aerospace Compliance Records That Must Outlive the AI Itself
Automated AS9100 recordkeeping solves today's audit burden but creates a traceability gap when the generating system is retired before the aircraft is.
The Architecture Question Behind AI Agents in Air Traffic Control
As AI agents are proposed to manage rising air traffic, the unresolved decision is architecture and assurance, not model capability.
The Certification Gate for Cage-Free Robots
Third-party functional safety certification, not vendor claims, is becoming the real capital gate for deploying autonomous robots on industrial floors without barriers.
The Compliance Evidence Layer Is Becoming Infrastructure
Open governance tooling, revised ISO 9001 rules, and national mandates are converging on one requirement: compliance evidence must be structured data, not paperwork.
The Compression Blind Spot in Aerospace AI Assurance
Edge AI models shrunk by 99% for aerospace and defense inference lack a certification pathway to treat compression as a qualifiable design change.
Europe's New Fast Lane for Breakthrough AI Devices Comes With No Governance Shortcut
The EU's new Breakthrough Devices framework under MDR/IVDR speeds review timelines but leaves AI governance obligations fully intact.
Static Categories, Adaptive Systems: The Real Fault Line in AI Device Review
FDA and EU sandbox pilots for agentic AI are one symptom of a broader breakdown in static regulatory categories, and buyers should treat both the hype and the early-engagement tradeoffs with equal scrutiny.
The Grid Is Now Trusting AI's Own Numbers
AI vendors claim they can unlock grid capacity and cut power volatility, but utilities are making capital decisions on unaudited performance figures.
The New Fault Line: When Identical Hardware Faces Opposite FDA Rules
FDA's finalized wearable guidance means device classification now hinges on claims and labeling, turning product marketing into a regulatory control point.
The Paperwork Problem Nobody's AI Has Solved
Aerospace's fragmented certification landscape is a procurement risk that ISO 42001 and EU AI Act conformity obligations are built to catch, if buyers ask.
The ISO 42001 Gap: When AI Enters the Control Loop
ISO 42001 certifies AI management systems, not real-time physical control performance, and that distinction matters as AI moves into grids, factories, and robots.
When AI Guides the Scan, Governance Must Follow the Hands
FDA's clearance of real-time AI ultrasound guidance software shifts imaging AI governance from diagnostic accuracy to human-AI interaction validation.
The Trial Matching Black Box
Agentic AI that extracts and standardizes EHR data for oncology trial matching is becoming clinical trial infrastructure with no validation framework behind it.
Machine Safety Certification Is Becoming a Stack, Not a Stamp
Industrial AI systems now need functional safety, AI governance, and sector regulation layered together, and buyers should verify each layer separately.
Who Signs Off When AI Triages an Airworthiness Directive
Agentic AI is entering AD and SB processing in MRO, raising a hard question about audit trails and accountability under FAA and EASA continued airworthiness rules.
When AI Becomes the Safety System, Certification Changes
As AI takes over hazard detection and shutdown decisions on factory floors, buyers must certify the algorithm, not just the machine guard.
The Parts Certification Stack Has No Line for AI
Aviation distributors carry a dense stack of quality certifications, but none of them govern AI now used to verify parts provenance and documentation.
The Continuous-Update Trap in Medical AI Governance
FDA now lets manufacturers update AI devices without new submissions, but EU's MDR/IVDR and AI Act stack offers no equivalent, forcing a split lifecycle strategy.
The Decoupled Diagnostic: Who Owns the Scan
FDA's clearance of AI that lets non-specialists capture diagnostic scans creates a workflow no existing device framework was built to assign liability for.
FDA Loosens the Data Bar. The EU Hasn't Said It Will Follow.
FDA's new real-world evidence flexibility for AI devices creates a sequencing risk for manufacturers still reconciling MDR/IVDR and EU AI Act data governance demands.
When the Test Tool Itself Needs a Certificate
AI is moving into avionics test benches, and DO-330 tool qualification rules were never built for nondeterministic outputs.
Self-Verifying AI Doesn't Mean Self-Qualifying
Agentic AI is moving into aerospace design and engineering tooling, but DO-330 tool qualification still governs whether any of that verification counts.
When the Scientist Is an Agent: Governing AI Before It Reaches the IND
Ono Pharmaceutical's rollout of agentic AI to every discovery scientist exposes a governance gap that sits upstream of any device or wearable regulation.
When AI Stops Advising the Grid and Starts Running It
Closed-loop AI now actuates power infrastructure directly, and neither ISO 42001 nor current EU AI Act debates settle who governs that authority.
Aerospace Is Buying AI Faster Than It Can Certify It
AI is spreading across avionics, defense electronics, and design tooling while EASA and FAA certification methodology for airborne AI remains unfinished.
Certifying the Pilot, Not Just the Plane
Trainer aircraft are teaching pilots to fly alongside autonomous wingmen, but no certification standard yet defines competency in human-autonomy teaming.
Energy and Industrial AI: Compliance Before the Rules Are Written
With no coherent US AI framework and federal-state tension over infrastructure rules, energy and industrial operators should build to the strictest tested standard now.
The Benchmark Gap Inside FDA's AI Change Control Plans
FDA's Predetermined Change Control Plan guidance lets AI devices update without new submissions, but no validated benchmarking standard tells manufacturers where drift becomes risk.
One Algorithm, Two Rulebooks: The Wearable AI Compliance Gap
FDA's looser wellness classification for AI wearables collides with the EU AI Act's stricter high-risk tiering, forcing global device makers to design for the harder standard first.
Who Signs the Drawing When the Engineer Is an Agent
Agentic AI is entering aerospace design work, and no framework yet defines who holds design authority when an AI agent authors engineering artifacts.
The Real AAM Bottleneck Is the Supervisor, Not the Aircraft
Wisk and NASA's multi-aircraft supervision trial exposes a certification gap that matters more than autonomy readiness for Advanced Air Mobility.
AI Is Moving Into the Test Bench, Not Just the Cockpit
AI-driven test and measurement tools are entering aerospace V&V workflows, raising tool-qualification questions that certification debates about airborne AI have not yet addressed.
Retrofitting Autonomy Into Certified Freighters Changes the Buyer's Question
Merlin and IAI's push to certify autonomous flight systems on existing Part 25 cargo airframes shifts the compliance question from airworthiness to operational assurance.
Microgrids, AI Campuses, and an Untested Compliance Assumption
Bespoke AI campus microgrids are multiplying faster than anyone has tested whether their instability actually voids an AI Act or ISO 42001 file.
Capital Is Flowing to AI. Regulatory Science Capacity Is Not.
EU device rules, FDA benchmarking, and pharma's AI rollout share one constraint: regulators lack the evidence infrastructure to keep pace with deployment.
PCCP Is Settled. The Benchmarks Underneath It Are Not.
FDA's change control pathway for AI-enabled devices is mature, but the benchmarking standards sponsors need to use it well are still unresolved.
Your Patients Are Uploading Health Data Into a Regulatory Gap
Life sciences firms building patient-facing AI tools are relying on a HIPAA and FDA perimeter that consumer health AI routinely sits outside.
Shared AI Safety Tools, No Accountable Owner
A joint runway incursion initiative and AI-driven safety reporting tools push AI into cross-organizational safety decisions without a clear accountability structure.
Two Defense AI Claims, Zero Independent Verifiers, One Week
KAI's in-house UAV AI verification and Safe Pro's trade-show validation show how little civil frameworks like ISO 42001 or the EU AI Act reach into defense AI assurance.
FDA's AI Perimeter Is Widening and Narrowing at the Same Time
FDA is loosening wellness device classification while tightening AI change control mechanics, and the gap between the two is where compliance risk now sits.
The Grid AI Decision Is a Data Custody Decision
For energy operators buying AI grid-optimization tools, the architecture choice between vendor-owned sensors and OT data access sets the cybersecurity liability line.
The Benchmarking Gap FDA Hasn't Closed
Nature Medicine's new framework for evaluating generalist medical AI outpaces FDA's device-modification tools, leaving capability-tier governance to buyers.
Who Owns the Stop Decision
As safety motion control systems halt machines without human confirmation, regulated buyers need contractual proof of accountable ownership, not just certification.
The Assurance Gap Behind Every AI Autonomy Pitch
Aerospace certification data from Farnborough exposes a wider governance problem: many AI autonomy and risk-detection claims have no equivalent conformity regime at all.
The Guidance Cannot Outrun the Model
FDA and EU regulators are structurally too slow to govern AI at the pace it changes, so life sciences compliance leaders must build internal governance now.
The Rulebook Is Being Written While the Machines Run
International standards bodies are drafting industrial AI rules in real time, forcing compliance leaders to build on existing frameworks rather than wait for finished ones.
The Grid Is Becoming a Control Loop, But the Case Isn't Closed
AI is moving from grid advisory to grid execution, but the pace is a bet on scaling, not a settled fact, and assurance regimes haven't caught up either way.
The Watching Layer Gets Regulated Too
As AI-based safety monitoring scales across industrial sites, the surveillance systems themselves are becoming a governance and cybersecurity liability, not just a sensor purchase.
When Health Data Leaves the Regulated Perimeter
FDA's wellness classification determines more than marketing claims. It decides whether patient data uploaded to AI tools carries any regulatory protection at all.
The Real Bottleneck on the Floor Is the Certificate, Not the Robot
Cooperative safety certification, not AI capability, is now the gating factor for deploying humanoid robots and automation on industrial floors.
Certification Is the Signal, Not the Order Book
GE Aerospace's dual FAA/EASA certifications and Vertical Aerospace's conditional pre-orders show why regulated buyers must separate airworthiness proof from commercial narrative.
The Real Gate on Industrial AI Isn't the Model. It's the Safety Case.
As AI moves from dashboards to actuators on the plant floor, functional safety certification becomes the binding constraint on deployment, not model performance.
FDA Just Moved the Wellness Line. That Is a Liability Decision, Not a Compliance Break
FDA's broadened wellness classification for AI-enabled wearables forces life sciences leaders to choose their liability posture, not just their regulatory burden.
